Monitoring Supportive Care Needs in Lung Cancer and Melanoma Patients Using Telenursing
Randomized Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies
This study is testing if using a telenursing platform for support can help lung cancer and melanoma patients better manage their care when starting new treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rome) |
| Trial ID | NCT06254196 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of telenursing interventions for patients with lung cancer and melanoma who are candidates for their first prescription of targeted therapies. Patients will be randomized into two groups: one receiving standard clinical care and the other utilizing a telenursing platform for enhanced monitoring and support. The study aims to assess the impact of these interventions on the supportive care needs of patients over a one-month period. Data will be collected through questionnaires and communication via a dedicated telephone line.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 with lung cancer or melanoma who are starting targeted therapies and can engage with technology.
Not a fit: Patients who are not suffering from lung cancer or melanoma, or those already undergoing treatment with targeted therapies, will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the supportive care experience and outcomes for patients undergoing targeted therapies.
How similar studies have performed: While the use of telenursing is gaining traction, this specific approach for lung cancer and melanoma patients is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged between 18 and 75; * patients suffering from lung cancer and melanoma candidates for the first prescription with Targeted Therapies in exclusive treatment; * patients able to understand, speak Italian and join the study by signing of paper informed consent; * possibility of accessing and using the information technologies adopted in trial through a PC/tablet and personal internet connection; * patients willing to comply with study procedures. Exclusion Criteria: * patients not suffering from lung cancer or melanoma; * patients already treated or currently being treated with Targeted Therapies, or other treatment (chemotherapy and/or radiotherapy and/or exclusive palliative care); * patients with cognitive problems, psychiatric disorders and poor compliance who could interfere with study participation.
Where this trial is running
Rome
- "Regina Elena" National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Principal investigator: Aurora De Leo, Nursing — IRCCS "Regina Elena" National Cancer Institute
- Study coordinator: Aurora De Leo, Nursing
- Email: aurora.deleo@ifo.it
- Phone: 0652662928
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.